It refers to a system
making it obligatory to have compounds (low molecular weight organic compounds and single-ingredient natural products) obtained through state-
run R&D projects entrusted to a designated institution. The compounds are systematically preserved and managed at the said institution and
provided to researchers developing new drugs at businesses, universities, and research institutes.
The KRICT (KCB) is designated as
an institution dedicated to management and distribution of compounds obtained as research results (MISP Notice No. 2013-128). Please contact us
and we can send you a container (vial or rack) for storing compounds. Upon your entrustment of compounds, we issue you a compound receipt for
your use in project evaluation or submittal of relevant reports.
Please entrust compounds with
molecular weight of 100-1,000 with high potential for development as new drugs.
We prefer to receive compounds with 90% or more in purity and 10mg or more in amount. As for natural products, we receive only single-isolated
We check the purity and molecular weight of entrusted compounds
and then store them at a low-temperature (- 5℃). Upon a request from a biological activity testing institution, they are used for exploration
of new drug-related research through HTS on specified targets or exploration of tool chemicals in bio research.
Entrusted compounds are systematically managed by KCB and
anyone in the country can use them. When an entrusted compound displays activity in a drug biological activity test, the entrustor may take
part in ensuing research through an arrangement made with the user or share relevant proceeds (if applicable).
Please submit a biological activity test application to KCB.
Then, we provide the compound to you if it does not overlaps one of the ongoing tests.
you can. If a biological activity testing institution submit an application, specifying the skeleton it is interested in, it can carry out a
test by selecting only the relevant compounds.
No, we don’t. The role
played by us is to link an entrusting institution with a biological activity testing institution by providing entrusted compounds to a testing
institution after storing them systematically. We may purchase chemical derivatives and provide them to a testing institution if necessary in
the course of hit evaluation.
In such a case, we refuse to provide the compound in question to protect the rights of the
institution that started the drug efficacy test first. However, we may provide the compound in question in special cases, when it is highly
likely that different hits will occur due to the difference in the compounds provided for the test or the use of different test methods.
early hit is obtained as a result of a biological activity test, validity evaluation study can be carried out, which will not last for more
than six months. When it is deemed that the valid substance is worth developing (final hit), the testing institution and KCB sign an agreement
for joint research and proceed with the development research, with the testing institution playing a leading role. If the testing institution
insists, it may proceed with the development alone after paying the expense for using the compound to KCB.